News. 04. Forensic Logic Announces Acquisition of COPLINK Platform from IBMThe acquisition will create the nations largest network of law enforcement users, information, and technology. WALNUT CREEK, CA and TUCSON, AZ October 4, 2. Forensic Logic, the premier provider of network search technology and cloud based information services to law enforcement, today announced it has acquired the COPLINK suite of products from IBM. COPLINK is a leading public safety information sharing platform and provider of analytical, tactical and operational software for law enforcement. The acquisition will deliver an unprecedented level of information access and technological interoperability to the U. S. law enforcement community, while greatly streamlining data integration, product acquisition, and customer service among their customer base. Created in 1. 99. COPLINK provides public safety software and services to over 5. Tgmvq9JcpAQ/WcztU7W_AvI/AAAAAAAANFI/D3weORaneR0igzJOSmVrMi-QhpMV3jhvQCLcBGAs/s1600/Trump-McMahon.jpg' alt='Omega Trust Prosperity Program Trusts' title='Omega Trust Prosperity Program Trusts' />11 Aiming at Soliris, Apellis loads for PNH phase III with 60M series E. By Marie Powers, News Editor, BioWorld. Apellis Pharmaceuticals Inc. Bermudas International and Local Companies and Limited Partnerships, M to Z Many offshore corporations shown here have worldwide interests. Deuteronomy Devotionals 1 Our Daily Bread Devotionals Deuteronomy Devotional Commentary. Compiled from Today in the Word Moody Bible Institute Also includes Our. Got debt,Convert debt to cash. Pay off Mortgage, Credit Card, Student Loan, IRS, Auto debt, Debt free, Educational Programs. Latest breaking news, including politics, crime and celebrity. Find stories, updates and expert opinion. I have already surpassed more days absent from posting than I have in more than ten years and the guilt is becoming more burdensome than the physical pain. The following database contains a searchable listing of grants the Foundation has awarded since 2003. Grants can be sorted in either direction by clicking on any one. This page has devotionals and sermon illustrations on Isaiah from Today in the Word, F B Meyer, G Campbell Morgan, C H Spurgeon, and many other sources. Find the latest Mid Cap Revenue ETF performance and returns on OppenheimerFunds. Get a snapshot of commentary, returns, share price and more. United States. In addition to its core analysis platform, the COPLINK system offers an integrated array of software solutions for investigations, operations, and compliance. Founded in 2. 00. Forensic Logic has become one of the fastest growing public safety technology providers in the country built on the success of its search engine optimized for public safety. The acquisition will further Forensic Logics strategy to deploy a fully integrated suite of world class information access technology across the widest possible network of public safety agencies. The COPLINK acquisition reinforces our commitment to bring a compelling combination of technological capabilities to this market, said Bob Batty, CEO of Forensic Logic. Our customers will no longer have to choose between the best search capability, the finest analytical tools, and the richest network of data once the integration is done they will all be on one platform. Stealth Bio. Therapeutics Granted Orphan Drug Designation of Elamipretide for Treatment of Patients with Primary Mitochondrial Myopathy. BOSTON October 2, 2. Stealth Bio. Therapeutics Stealth, a clinical stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced that the U. S. Food and Drug Administrations FDA Office of Orphan Products Development OOPD has granted Orphan Drug Designation to Stealths investigational drug candidate, elamipretide, for the treatment of patients with primary mitochondrial myopathy PMM. We are thrilled to achieve this key regulatory milestone for the treatment of PMM, a debilitating condition characterized by muscle weakness and fatigue with no FDA approved treatments, said Reenie Mc. Carthy, Stealths chief executive officer. We will continue to work closely with the FDA as we advance into our Phase 3 trial of elamipretide in patients with PMM. The Orphan Drug Act was enacted in 1. United States. Once granted, Orphan Drug Designation provides various development benefits for an investigational drug, including seven year exclusivity after marketing approval is received. In June 2. 01. 7, Stealth announced results from MMPOWER 2, a Phase 2 continuation trial evaluating safety, tolerability and efficacy of treatment with elamipretide for PMM, which showed benefit of elamipretide across multiple endpoints assessed and supports a Phase 3 trial in this patient population. Stealth is currently recruiting for the Re. POWER trial, an observational study of patients with PMM. Patients enrolled in Re. POWER may have the opportunity to participate in the Phase 3 trial to further evaluate the potential efficacy, safety and tolerability of elamipretide for patients with PMM. Nu. Cana Plc Announces Closing Of Initial Public Offering Of ADSs And Exercise Of Underwriters Option To Purchase Additional ADSs. EDINBURGH, United Kingdom, Oct. GLOBE NEWSWIRE Nu. Cana plc Nasdaq NCNA, a clinical stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying its Pro. Tide technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines, announced today the closing of its initial public offering of 7,5. American Depositary Shares ADSs at a price to the public of 1. ADS, which includes 9. ADSs, for total gross proceeds of approximately 1. Each ADS represents one ordinary share of Nu. Cana. The ADSs began trading on the NASDAQ Global Select Market on September 2. NCNA. All ADSs were offered by Nu. Cana. Citigroup, Jefferies and Cowen acted as joint book running managers for the offering, and William Blair acted as co manager for the offering. A registration statement on Form F 1 relating to these securities has been filed with the U. S. Securities and Exchange Commission the SEC and was declared effective on September 2. Copies of the registration statement can be accessed by visiting the SECs website at www. The offering was made only by means of a prospectus. Magix Music Maker 14 Activation Keygen Photoshop. Copies of the final prospectus relating to the offering may be obtained by contacting Citigroup Global Markets Inc., co Broadridge Financial Solutions, 1. Long Island Avenue, Edgewood, NY 1. Jefferies LLC, Attention Equity Syndicate Prospectus Department, 5. Madison Avenue, 2nd Floor, New York, NY 1. ProspectusDepartmentJefferies. Cowen and Company, LLC, co Broadridge Financial Solutions, 1. Long Island Avenue, Edgewood, NY 1. Attention Prospectus Department or by phone at 6. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction. Aduro Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Personalized Immunotherapy p. LADD Based on Proprietary Neoantigen Technology. Trial has begun in Patients with Metastatic Colorectal Cancer Who Have Few Treatment Options. BERKELEY, Calif., Sept. GLOBE NEWSWIRE Aduro Biotech, Inc. Nasdaq ADRO, a biopharmaceutical company with three distinct immunotherapy technologies, announced today that the first patient has been dosed in the Phase 1 clinical trial see www. NCT0. 31. 89. 03. Listeria monocytogenes p. LADD immunotherapy for adults with metastatic colorectal cancer that is microsatellite stable MSS. The personalized immunotherapy has been engineered with patient specific neoantigens that were identified and selected using state of the art neoantigen identification technology developed by Hanlee Ji, M. D., associate professor of medicine at the Stanford University School of Medicine. Our p. LADD program leverages our extensive capabilities relating to the use of Listeria as a delivery mechanism for cancer antigens and Dr. Jis innovative neoantigen technology used to identify immunogenic antigens specific for an individual patient, said Natalie Sacks, M. D., chief medical officer of Aduro Biotech. Together, we believe these two cutting edge technologies represent a new approach to treating patients who have relapsed following prior chemotherapy. We look forward to evaluating initial proof of concept in this Phase 1 clinical trial. Clinical Design of Phase 1 PLADD Trial in Adults with Metastatic Corlorectal Cancer. The Phase 1 clincial single arm trial is designed to evaluate the safety and tolerability of a personalized immunotherapy made using patient specific antigens and Aduros proprietary live, attenuated, double deleted Listeria monocytogenes platform technology. The trial is seeking to enroll approximately 1. MSS. Patients will receive their patient specific immunotherapy once every three weeks. Nu. Cana plc Announces Pricing of Initial Public Offering. EDINBURGH, United Kingdom, Sept. GLOBE NEWSWIRE Nu. Cana plc Nasdaq NCNA, a clinical stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying its Pro. Best Practices and Examples from Family Businesses. British statesman Lord Chesterfield recommended that Learning is acquired by reading books, but the much more necessary learning, the knowledge of the world, is only to be acquired by reading men, and studying all the various facets of them. We have discussed the topic of identity with a number of family businesses around the world in order to study the many different facets of those who are keenly aware of the importance of having a strong family identity.